FENC
Fennec Pharmaceuticals Inc.
$10.00
+$0.11(+1.11%)
52
Overall
40
Value
54
Tech
63
Quality
Market Cap
$236.01M
Volume
39.60K
52W Range
$5.65 - $9.92
Target Price
$15.57
Company Overview
| Mkt Cap | $236.01M | Price | $10.00 |
| Volume | 39.60K | Change | +1.11% |
| P/E Ratio | -24.2 | Open | $9.90 |
| Revenue | $44.6M | Prev Close | $9.89 |
| Net Income | $-9.7M | 52W Range | $5.65 - $9.92 |
| Div Yield | N/A | Target | $15.57 |
| Overall | 52 | Value | 40 |
| Quality | 63 | Technical | 54 |
No chart data available
About Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Sector: Healthcare
Industry: Biotechnology
Latest News
Fennec Showcases New PEDMARK Data at ASCO 2026
TipRanks Auto-Generated Newsdesk•5 days ago
Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC) and Sutro Biopharma (STRO)
Christine Brown•5 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | FENC | $10.00 | +1.1% | 39.60K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Fennec Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW